Format

Send to

Choose Destination
Trends Microbiol. 2020 Jan 10. pii: S0966-842X(19)30320-8. doi: 10.1016/j.tim.2019.12.005. [Epub ahead of print]

Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia.

Author information

1
Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Pavia, Italy.
2
GlaxoSmithKline, Siena, Italy.
3
Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Pavia, Italy. Electronic address: giovanna.riccardi@unipv.it.

Abstract

Cystic fibrosis (CF) patients are at particular risk of infection by microorganisms that are resistant to several antibiotics. About 3% of CF patients are colonized by Burkholderia cenocepacia, and this represents a major threat because of its intrinsic high level of drug resistance and the lack of a safe and effective treatment protocol. The development of anti-Burkholderia vaccines is a valuable and complementary approach, but only a few studies have been reported to date. In this review we discuss recent advances in the vaccine field and how new technologies, including structural reverse vaccinology, could drive the design of an effective vaccine against B. cenocepacia for use in preventive and therapeutic applications.

KEYWORDS:

antibiotic resistance; cystic fibrosis, Burkholderia cenocepacia; vaccines

PMID:
31932141
DOI:
10.1016/j.tim.2019.12.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center